AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03569241
Drug: androgen deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months
Trial: NCT00497458
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: testosterone 40 or 80 mg once a day
Trial: NCT00683527
Drug: Elemental iron
RxNorm normalized name: Elemental Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron in the dose of 3-4 mg/kg/day (of elemental iron) PO once daily mixed with expressed breast milk from 14 days of life till the end of study period
Trial: NCT03672721
Drug: IA Carbo+ Radiation
RxNorm normalized name: Carbo animalis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of intraarterial carboplatin + radiation in dose escalation
Trial: NCT01426100
Drug: CKD-828 40/2.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination of Telmisartan 40mg and S-Amlodipine 2.5mg
Trial: NCT01426100
Drug: CKD-828 40/5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination of Telmisartan 40mg and S-Amlidioine 5mg
Trial: NCT00107198
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00107198
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02625610
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction Phase: Leucovorin was administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
Trial: NCT02625610
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction Phase: Capecitabine was administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase every 3 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
Trial: NCT02625610
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction Phase: Leucovorin will be administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.
Trial: NCT02625610
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction Phase: Capecitabine will be administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.
Trial: NCT03654053
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken once nightly at bed time.
Trial: NCT03654053
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40mg taken once nightly at bed time.
Trial: NCT00699582
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
Trial: NCT02538705
Drug: Neovasculgen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04129528
Drug: CFZ533
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First dose is administered via intravenous infusion, subsequent doses are administered subcutaneously.
Trial: NCT04417660
Drug: M7824
RxNorm normalized name: M7824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa will be administered at a dose of 1200 mg intravenously once every two weeks until disease progression or development of intolerable adverse events.
Trial: NCT04197934
Drug: EGFR/EGFRvIII Inhibitor WSD0922-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01749228
Drug: Etodolac Capsules USP 300 mg
RxNorm normalized name: etodolac Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg capsule once a day
Trial: NCT01749228
Drug: Etodolac
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg tablet once a day
Trial: NCT01643889
Drug: Treatment A (domperidone 10 mg)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 domperidone 10 mg capsule four times a day (q.i.d.) + 1 domperidone placebo capsule q.i.d. on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
Trial: NCT01643889
Drug: Treatment C (placebo)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
Trial: NCT01643889
Drug: Treatment D (moxifloxacin)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin 400 mg capsule in the morning of Day 1.
Trial: NCT04069026
Drug: BAY2416964
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral application of study drug daily in a predefined dose escalation scheme.
Trial: NCT04069026
Drug: BAY2416964
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral application of study drug daily at the dose defined in the dose escalation scheme to determine the recommended phase 2 dose (RP2D).
Trial: NCT01299636
Drug: PM060184
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM060184 administered intravenously (i.v.) over 10 minutes at a starting dose of 4 mg/m2/day on three consecutive days q2w (on Days 1-3 and 15-17) every 28 days.
Trial: NCT00469443
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 200 mg/m2 infused over 2 hours IV, on day 1 and 2 every 2 weeks for 10 cycles
Trial: NCT00469443
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 2000mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
Trial: NCT00052013
Drug: PTK787/ZK 222584
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02536209
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03091920
Drug: IW-1973
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT03091920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT03143855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered twice daily for for 5 days
Trial: NCT00097474
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone will be given alone or in combination with Melatonin to see if symptoms of jet lag are alleviated
Trial: NCT00097474
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin will be given alone or in combination with Hydrocortisone to see if symptoms of jet lag are alleviated
Trial: NCT00097474
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03709264
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: standard treatment
Trial: NCT04023669
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT02576951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03511118
Drug: clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Trial: NCT03511118
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Trial: NCT03511118
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Trial: NCT03511118
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Trial: NCT03511118
Drug: Hydrocodone
RxNorm normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Trial: NCT00465894
Drug: Intra Vaginal Estradiol Cream
RxNorm normalized name: estradiol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-B estradiol cream 0.5 grams nightly for 6 weeks then two times weekly for 46 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks.
Trial: NCT03773978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT01186263
Drug: MAA for diagnostic SPECT imaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial application of 5ml containing 500.000 particles with an activity of 150MBq.
Trial: NCT01186263
Drug: Diagnostic B20- SPECT imaging.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial application of 5ml containing 150.000 particles with an activity of 150 MBq.
Trial: NCT04686474
Drug: Azadirachta indica leaves extract containing ointment intervention.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azadirachta indica leaves extract containing ointment, white petroleum, bee wax, stearyl alcohol
Trial: NCT00988494
Drug: Placebo ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular application
Trial: NCT00004563
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.
Trial: NCT00004563
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching gelcaps 25 mgs
Trial: NCT03715556
Drug: 0.9% physiological solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 0.9% physiological solution.
Trial: NCT03773640
Drug: Sonophoresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group ( II) consisted of 20 patients treated with occlusion splints and sonophoresis procedures. For the area of mastication muscles 0.9 W/cm² treatments were applied, the duty factor was 80%, the treatment time was 10 minutes, and the medical substance was 25%Voltaren gel.
Trial: NCT00437112
Drug: Human Insulin Inhalation Powder
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient specific dose, inhaled, before meals, 24 weeks
Trial: NCT01056822
Drug: 1
RxNorm normalized name: My1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue with same dose of MMF as patient was taking before randomisation
Trial: NCT04505774
Drug: P2Y12
RxNorm normalized name: Purinergic receptor subtype P2Y12 antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: added P2Y12 inhibitor
Trial: NCT01688362
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later. For the first injection patients will have 15ml of blood drawn. This blood will then be discarded in a biohazard container. A 6ml solution of 4ml 0.25% Bupivacaine, 1ml 40mg Kenalog, and 1ml 4mg Dexamethasone will be prepared. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the steroid solution using a 22g needle. A dry sterile dressing will be placed at the injection site.~For the second injection two weeks later patients will have 15 ml of blood drawn. This blood will then be discarded in a biohazard container. Using the same technique as in Visit 2, the investigator will inject a 6 ml solution of 2 ml sterile normal saline with 4 ml 0.25% Bupivacaine to the shoulder using ultrasound. A dry sterile dressing will be placed at the injection site.
Trial: NCT01633762
Drug: meropenem, gentamicin, vancomycin (together)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 days antibiotic treatment, per oral, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate; gentamycin 40 mg (Hexamycin®), solution; meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined to a cocktail (with approximately 100 ml of apple juice)
Trial: NCT01423500
Drug: VP16, ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
Trial: NCT01423500
Drug: VP16, ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
Trial: NCT00033332
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02688712
Drug: LY2157299
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small molecule inhibitor of transforming growth factor-beta signaling pathway
Trial: NCT02688712
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antimetabolite chemotherapy
Trial: NCT02688712
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antimetabolite chemotherapy
Trial: NCT00762164
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 milligrams
Trial: NCT02405689
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02234882
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04196231
Drug: IDegLira
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDegLira will be started at 16 dose steps (16 U insulin degludec plus 0.58 mg liraglutide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements doses of IDegLira will be titrated individually twice per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose \< 80 mg/dL). The daily dose of IDegLira could be titrated to 50 dose steps (50 U insulin degludec plus 1.8 mg liraglutide).
Trial: NCT01780883
Drug: melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01780883
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets of Circadin®
Trial: NCT04196231
Drug: IGlarLixi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGlarLixi will be started at 10 dose steps (10 U insulin glargine plus 5 mcg lixisenatide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements, doses of IGlarLixi will be titrated individually once per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose \< 80 mg/dL). The daily dose of IGlarLixi could be titrated to 60 dose steps (60 U insulin degludec plus 20 mcg lixisenatide).
Trial: NCT03563716
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Trial: NCT04521478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02829060
Drug: Gentamicin, 5mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri-operative dose: 5 mg/kg of ideal body weight, IV
Trial: NCT02829060
Drug: Gentamicin, 80 mg, 7d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 day course, 80 mg daily, IM or IV
Trial: NCT04300231
Drug: injectable saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL
Trial: NCT02485834
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral 800 mg/m\^2 BID
Trial: NCT04196231
Drug: Insulin/Canaglifozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to canaglifozin, according to the current clinical practice and the drugs' data sheet. Canagliflozin will be started at 100 mg daily per oral administration, and augmented to 300 mg/per day if required (HbA1c \>7.5 after 12 weeks).
Trial: NCT00742612
Drug: ARC1779 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The ARC1779 treatment group will be dosed to achieve a target ARC1779 steady-state plasma concentration of 3 Ug/mL, using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
Trial: NCT01064388
Drug: AZD9742
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion, 15 days
Trial: NCT01064388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion, 15 days
Trial: NCT03745326
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
Trial: NCT03139305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of saline for 72 hours
Trial: NCT04046445
Drug: ATP128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-6 SC injections
Trial: NCT03522246
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be administered twice daily
Trial: NCT03522246
Drug: Placebo IV Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV placebo will be administered once every 4 weeks
Trial: NCT04032964
Drug: DOXORUBICIN
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 75 mg/m2 will be administered on day 1 of each 21-day cycle
Trial: NCT01391962
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic for hand foot syndrome as needed.
Trial: NCT01391962
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Replacement therapy for participants with increases in thyroid-stimulating hormone.
Trial: NCT03041740
Drug: Perfluorooctyl Bromide
RxNorm normalized name: perfluorooctyl triethoxysilane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the PFOB group will receive PFOB partial liquid ventilation instilled via side port of endotracheal tube (2.5 mL/kg/day) across 10 treatment days.
Trial: NCT00392327
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00054886
Drug: SU-011,248
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01404819
Drug: Standard anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients undergo standard anesthesia (remifentanil with propofol)